Interferon Treatment in Polycythaemia Vera

References

• Berlin N. I. Diagnosis and classification of the polycythemias. Seminars in Hematology 1975; 12: 339–351
   PubMed Web of Science ®Google Scholar
• Adamson J. W., Fialkow P. J., Murphy S., Prchal J. F., Steinmann L. Polycythemia vera: stem cell and probable clonal origin of the disease. New England Journal of Medicine 1976; 295: 913–919
   PubMed Web of Science ®Google Scholar
• de Th Wolf J. M., Beentjes J. A. M., Esselink M. T., Smit J. W., Halle M. R., Clark S. C., Vellenga E. In polycythemia vera human IL-3 and GM-CSF enhance erythroid colony forming growth in the absence of erythroietin. Experimental Hematology 1989; 17: 981–983
   PubMed Web of Science ®Google Scholar
• de Th Wolf J., Hendriks D. W., Esselink M. T., Halie M. R., Vellenga E. The effects of IL-1 and IL-4 on the Epo independent erythroid progenitor in polycythemia vera. British Journal of Haematology 1994; 80: 242–246
   Google Scholar
• Muller E. W., Th J. M., Hendriks D. W., Esselink M. T., Halie M. R., Vellenga E. Recombinant human mast cell growth factor supports erythroid colony formation in polycythemia vera in the presence and absence of erythropoietin and serum. Experimental Haematology 1995; 21: 1353–1357
   Web of Science ®Google Scholar
• Correa P. N., Eskinazi D., Axelrad A. A. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-I in vitro: studies in an improved serum-free medium. Blood 1994; 83: 99–112
   PubMed Web of Science ®Google Scholar
• Dai C. H., Krantz S. B., Dessypris E. N., Means R. T., Horn S. T., Gilbert H. S. Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony stimulating factor. Blood 1992; 80: 891–899
   PubMed Web of Science ®Google Scholar
• Berk P. D., Golsberg G. D., Donovan P. B., Fruchtman S. M., Berlin N. J., Wasserman L. R. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Seminars in Haematology 1986; 23: 132–143
   PubMed Web of Science ®Google Scholar
• Landaw S. A. Acute leukemia in polycythemia vera. Seminars in Haematology 1986; 23: 156–165
   PubMed Web of Science ®Google Scholar
• Kaplan M. E., Mack K., Goldberg J. D., et al. Long-term management of polycythemia vera with hydroxyurea. Seminars in Haematology 1986; 23: 167–171
   PubMed Web of Science ®Google Scholar
• Löfvenberg E., Wahlin A. Management of polycythemia vera, essential thrombocythemia and myelofibrosis with hydroxyurea. European Journal of Haematology 1988; 41: 375–381
   PubMed Web of Science ®Google Scholar
• Weinfeld A., Swolin B., Westin J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications. European Journal of Haematology 1994; 52: 134–139
   PubMed Web of Science ®Google Scholar
• Nand S., Messmore H., Fisher S. G., Bird M. L., Schultz W., Fischer R. I. Leukemic transformation in polycythemia vera: analysis of risk factors. American Journal of Haematology 1990; 34: 32–36
   PubMed Web of Science ®Google Scholar
• Salem H. H., Van der Weyden M. B., Young I. F., Wiley J. S. Pruritus and severe iron deficiency in polycythaemia. British Medical Journal 1982; 285: 91–92
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H. M., McCredie K., Trujillo J. M., Keating M. J., Gutterman J. U. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. New England Journal of Medicine 1986; 314: 1065–1069
   PubMed Web of Science ®Google Scholar
• Talpaz M., Mavligit G., Keating M, Walters R. S., Gutterman J. U. Human leukocyte interferon to control thrombocytosis in chronic myeloid leukaemia. Annals of Internal Medicine 1983; 99: 789–792
   PubMed Web of Science ®Google Scholar
• Ludwig H., Linkesch W., Gisslinger H., Fritz E., Sinzinger H., Radaszkiewicz T., Chott A., Roswitha F., Micksche M. Interferon alfa corrects thrombocytosis in patients with myeloproliferative disorders. Cancer Immunology Immunotherapy 1987; 25: 266–273
   PubMed Web of Science ®Google Scholar
• Giles F. J., Gray A. G., Brozovic M., Grant I. D., Machin S. J., Richards J. D. M., Venutas S., Singer C. R., Yong K. L., Davies S. C., Hoffbrand A. U., Mehta A. B., Thomas M. J. G., Goldstone A. Alpha-interferon therapy for essential thrombocythaemia. Lancet 1988; 2: 70–72
   PubMed Web of Science ®Google Scholar
• Barosi G., Libertato L. N., Costa A, Ascari E. Cytoreductive effects of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia. Blut 1989; 58: 271–274
   PubMedGoogle Scholar
• Silver R. T. Interferon-α2b: a new treatment for polycythemia vera. Annals of Internal Medicine 1993; 119: 1091–1092
   PubMed Web of Science ®Google Scholar
• Cacciola E., Giustolisi R., Guglielmo P., Di Raimondo F., Cacciola E., Calogero R. D. Recombinant interferon α in the treatment of polycythemia vera. Blood 1991; 77: 2790
   PubMed Web of Science ®Google Scholar
• Turn D., Mitra M. E., Di Trapani R., Lipani M. G., Perricone R., Cajozzo A. Interferon in polycythemia vera and essential thrombocythemia. Haematologica 1991; 76: 75–77
   Google Scholar
• de Th Wolf J. M., Hendriks D. W., Egger R. C., Esselink M. T., Halie M. R., Vellenga E. α-interferon for intractable pruritus in polycythemia vera. Lancet 1991; i: 241
   Web of Science ®Google Scholar
• Messora C., Bensi L., Vecchi A., Longo R., Giacobbi F., Temperani P., Bevini M., Emilia G., Sacchi S. Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. British Journal of Haematology 1994; 86: 402–404
   PubMed Web of Science ®Google Scholar
• Papineschi F., Bucalossi A., Capochiani E., Benedetti E., Bramanti E., Dastoli G., Dispensa E., Benedetti E., Spremolla G. Recombinant α2a interferon and polycythemia vera: Clinical results and biological evaluation by means of Fourier-transform infrared microspectroscopy. European Journal of Haematology 1994; 53: 213–217
   PubMed Web of Science ®Google Scholar
• Muller E. W., Th J. M., Egger R., Wijermans P. W., Huijgens P. C., Halie M. R., Vellenga E. Long-term treatment with interferon-α2b for severe pruritus in patients with polycythaemia vera. British Journal of Haematology 1995; 89: 313–318
   PubMed Web of Science ®Google Scholar
• Taylor P. C., Dolan G., Ng J-P, Paul B., Collin R., Reilly J. T. Efficacy of recombinant interferon alpha (rIFNα) in polycythaemia vera: a study of 17 patients and an analysis of published data. British Journal of Haematology 1995, (in press)
   Web of Science ®Google Scholar
• Giles F. J., Gray A. G., Carmichael D. S., Williams Y. F., Brosovic M., Goldstone A. H. Resistant polycythaemia vera successful therapy with non recombinant or recombinant alpha interferon. British Journal of Haematology 1991; 77((suppl 1))663
   Google Scholar
• Brand C. M., Leadbeater L., Budiman R., Lechner K., Gisslinger H. Successful re-treatment of an anti-interferon resistant polycythaemia vera patient with lymphoblastoid interferon-αN1 and in vitro studies on the specificity of the antibodies. British Journal of Haematology 1994; 86: 216–218
   PubMed Web of Science ®Google Scholar
• Castello G., Lerza R., Cerruti A., Cavallini D., Bogliolo G., Pannacciulli I. The in vitro and in vivo effect of recombinant interferon α-2a on circulating haemopoietic progenitors in polycythaemia. vera. British Journal of Haematology 1994; 87: 621–623
   PubMed Web of Science ®Google Scholar
• Teofili L., De Stefano V., Iovino M. S., Voso M. T., Tartaglione R., Bizzi B., Leone G. Disappearance of spontaneous erythroid colonies in patients with myeloproliferative disorders treated by alpha interferon. British Journal of Haematology 1992; 81: 310–311
   PubMed Web of Science ®Google Scholar
• Finelli C., Gugliotta L., Gamberi B., Vianelli N., Visani G., Tura S. Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa. American Journal of Haematology 1993; 43: 316–318
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Deisseroth A., Kurzrock R., Estrov Z., Talpaz M. Chronic myelogenous leukaemia: a concise update. Blood 1993; 82: 691–703
   PubMed Web of Science ®Google Scholar
• Tura S., Baccarani M., Zuffa E., Russo D., Fanin R., Zaccaria A., Fiacchini M. and the Italian Cooperative Study Group on chronic myeloid leukaemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukaemia. New England Journal of Medicine, 330: 820–825
   PubMed Web of Science ®Google Scholar
• Yoffe G., Blick M., Kantarjian H. M., Spitzer G., Gutterman J., Talpaz M. Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukaemia. Blood 1987; 69: 961–963
   PubMed Web of Science ®Google Scholar
• Swolin B., Weinfeld A., Westin J. A prospective long-term cytogenetic study in polycythemia in relationship to treatment and clinical course. Blood 1988; 72: 386–395
   PubMed Web of Science ®Google Scholar
• Hino M., Futami E., Okuno S., Miki T., Nishizawa Y., Morii H. Possible selective effects of interferon α-2b on a malignant clone in a case of polycythemia vera. Annals of Haematology 1993; 66: 161–162
   PubMed Web of Science ®Google Scholar
• Gale R. E., Wainscoat J. S. Clonal analysis using X-linked DNA polymorphisms. British Journal of Haematology 1993; 85: 2–8
   PubMed Web of Science ®Google Scholar
• Wasserman L. R. The treatment of polycythemia vera. Seminars in Haematology 1976; 13: 57–78
   PubMed Web of Science ®Google Scholar
• Fjellner B., Hägermark O. Pruritus in polycythemia vera: treatment with aspirin and possibility of platelet involvement. Acta Dermatology and Venereology 1979; 59: 505–512
   PubMed Web of Science ®Google Scholar
• Steinman H. K., Kobza-Black A., Lotti T. M., Brunetti L., Panconesti E., Greaves M. W. Polycythaemia vera and water induced pruritus: blood histamine levels and cutaneous fibrinolytic activity before and after water challenge. British Journal of Dermatology 1987; 116: 329–333
   PubMed Web of Science ®Google Scholar
• Gilbert H. S., Warner R. R. P., Wasserman L. R. A study of histamine in myeloproliferative disease. Blood 1966; 28: 795–806
   PubMed Web of Science ®Google Scholar
• Swerlick R. A. Photochemotherapy treatment of pruritus associated with polycythemia vera. Journal of the American Academy of Dermatology 1995; 13: 675–677
   Web of Science ®Google Scholar
• Denman S. T. A review of pruritus. Journal of American Academy of Dermatology 1986; 14: 375–392
   PubMed Web of Science ®Google Scholar
• Jackson N., Burt D., Crocker J., Boughton B. Skin mast cells in polycythaemia vera: relationship to the pathogenesis and treatment of pruritus. British Journal of Dermatology 1987; 116: 21–29
   PubMed Web of Science ®Google Scholar
• Chanarin I., Szur L. Relief of intractable pruritus in polycythemia rubra vera with cholestyramine. British Journal of Haematology 1975; 29: 669–670
   PubMed Web of Science ®Google Scholar
• Weick J. K., Donovan P. B., Najean Y., Dresch C., Pisciotta A. V., Cooperberg A. A., Goldberg J. D. The use of cimetidine for the treatment of pruritus in polycythemia vera. Archives of Internal Medicine 1982; 142: 241–242
   PubMed Web of Science ®Google Scholar
• Hoffman R., Boswell H. S. Polycythemia vera. Hematology: Basic Principles and Practice, R. Hoffman, E. J. Benz, S. J. Shattil, B. Furie, H. J. Cohen, L. E. Silberstein. Churchill Livingstone, New York 1995; 1121–1142
   Google Scholar
• Ariad S., Bezwoda W. R. α-interferon for polycythemia vera. Blood 1991; 77: 670
   PubMed Web of Science ®Google Scholar
• Dallman P. R., Beutler E., Finch C. A. Effects of iron deficiency exclusive of anaemia. British Journal of Haematology 1978; 40: 179–184
   PubMed Web of Science ®Google Scholar
• Rector W. G., Fortuin N. J., Conley C. L. Nonhematologic effects of chronic iron deficiency: a study of patients with polycythemia vera treated solely with venesections. Medicine (Baltimore) 1982; 61: 382–389
   PubMed Web of Science ®Google Scholar
• Silverstein M. N. The evolution into and the treatment of late stage polycythemia vera. Seminars in Haematology 1976; 13: 79–84
   PubMed Web of Science ®Google Scholar
• Ascari E., Baresi G., Carlo-Stella C., Cazzola M., Dazza L., Ganser A., Meloni F., Melzer D., Pedrazzoli P. Effects of recombinant and gamma interferons on the in vitro growth of circulating hematopoietic stem cells (CFU-GEMM, CFU-MK, BFU-C and CFU-GM) from patients with myelofibrosis and with myeloid metaplasia. Blood 1987; 70: 1014–1019
   PubMed Web of Science ®Google Scholar
• Carlo-Stella C., Ganser A., Greher J., Hoelzer D., Vokers B. Effects of recombinant interferons alpha and gamma on human bone marrow derived megakaryocyte progenitor cells. Blood 1987; 70: 1173–1179
   PubMedGoogle Scholar
• Lin S. L., Kikuchi T., Pledger W. J., Tamm I. Interferon inhibits the establishment of competence in G°/S phase transition. Science 1986; 233: 356–359
   PubMed Web of Science ®Google Scholar
• Reilly J. T. Pathogenesis of idiopathic myelofibrosis: present status and future directions. British Journal of Hematology 1994; 88: 1–8
   PubMed Web of Science ®Google Scholar
• Gasti G., Lang A., Huber C., Seewann H. Interferon alpha for idiopathic myelofibrosis. Lancet 1988; i: 765–766
   Google Scholar
• Hasselbalch H. Interferon in myelofibrosis. Lancet 1988; i: 355
   Google Scholar
• Parmeggiani L., Ferrant A., Rodhain J., Michaux J. L., Sokal G. Alpha interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia. European Journal of Haematology 1987; 39: 228–232
   PubMed Web of Science ®Google Scholar
• Seewan H. L., Gastl G., Lang A., Abbrederis K., Thaler J., Flener R., Huber C. Interferon alpha 2 in the treatment of idiopathic myelofibrosis. Blut 1988; 58: 15–19
   Google Scholar
• List A. F., Doll D. C. Alpha-interferon in the treatment of idiopathic myelofibrosis. British Journal of Haematology 1992; 80: 566–567
   PubMed Web of Science ®Google Scholar
• Amarto E. P., Byrne M. H., Grantstein R. D., Margolis R. J., Murphy C. F. Gamma interferon inhibits collagen synthesis in vivo in the mouse. Journal of Clinical Investigation 1987; 79: 1254
   PubMed Web of Science ®Google Scholar
• Martyré M-C, Magdelenat H., Calvo F. Interferon-γ in vivo reverses the increased platelet levels of platelet-derived growth factor and transforming growth factor-β in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology 1991; 77: 431–435
   PubMed Web of Science ®Google Scholar
• Clemens M. Interferons and oncogenes. Nature 1986; 313: 531–532
   Web of Science ®Google Scholar